As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY ...

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic ...

Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment ...

French pharma giant Sanofi (NASDAQ:SNY) has agreed to sell global rights linked to Enjaymo, an FDA-approved treatment for an ...

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed ...

Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to ...

Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi ...

Recordati will acquire global rights to Enjaymo for $825M upfront and up to $250M in milestone payments. Enjaymo generated €100M in revenue in 2024 and is expected to exceed €150M in 2025 ...